Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
2014: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2017 - 2016 - 2015 - 2014

February 2014 Scleroderma News

Management of cutaneous discomfort in patients with scleroderma: a clinical trial. This study verified the efficacy of two formulations, specifically designed to wash, moisturize and soothe the scleroderma skin, especially in association with Iloprost therapy. PubMed, Reumatismo, 2013 Dec 18;65(5):240-7. (Also see Photos of Sclerodactyly)

Correlations between nailfold microangiopathy severity, finger dermal thickness (DT) and fingertip blood perfusion (FBP) in systemic sclerosis patients (SSc). This study demonstrates a relationship between nailfold microangiopathy severity, DT and FBP in SSc patients. PubMed, Ann Rheum Dis, 2014 Jan 1;73(1):247-51. (Also see Vascular Involvement in Systemic Scleroderma)

Impaired in vivo neovascularization capacity of endothelial progenitor cells (EPC) in patients with systemic sclerosis (SSc). EPCs contribute to vascularization by being incorporated into vessel walls and by differentiating into endothelial cells and these EPC functions are impaired in SSc patients. PubMed, Arthritis Rheum, 2013 Dec 24. (Also see Causes of Scleroderma: Endothelin)

Expert consensus for performing right heart catheterisation (RHC) for suspected pulmonary arterial hypertension in systemic sclerosis (SSc): a Delphi consensus study with cluster analysis. Among experts in pulmonary arterial hypertension-SSc, a core set of criteria for clinical practice to refer SSc patients for RHC has been defined by Delphi consensus methods. PubMed, Ann Rheum Dis, 2014 Jan 1;73(1):191-7. (Also see Pulmonary Hypertension and Right Heart Catheterization)

The enhanced liver fibrosis (ELF) test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. The ELF test significantly correlates with several measures of fibrosis in SSc and with overall disease activity, severity and health assessment questionnaire-disability index. PubMed, Ann Rheum Dis, 2014 Feb 1;73(2):420-7. (Also see Liver Involvement)

Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis. Levels of CXCL4 were elevated in patients with systemic sclerosis and correlated with the presence and progression of complications, such as lung fibrosis and pulmonary arterial hypertension. The New England Journal of Medicine, 12/18/2013. (Also see Biomarkers, Pulmonary Hypertension and Pulmonary Fibrosis)

Prevalence of ocular manifestations in systemic sclerosis patients. In patients with systemic sclerosis, numerous abnormalities with vision may be found and regular ophthalmological examinations are essential. Archives of Medical Science, 12/28/2013. (Also see Eye Involvement)

Connective Tissue Disease-Associated Interstitial Lung Disease (CTD): A Focused Review. The prognosis of patients with CTD having respiratory failure is often quite poor, highlighting the need for prompt and thorough clinical assessments to determine the underlying etiology and implementation of appropriate therapeutic strategies. PubMed, J Intensive Care Med, 2013 Dec 25. (Also see Lung Involvement Prognosis and Connective Tissue Disease)

Iron deficiency (ID) in systemic sclerosis (SSc) patients with and without pulmonary hypertension (PH). ID is more prevalent in SSc-PH than in SSc-nonPH patients and is associated with exercise impairment in both SSc-PH and SSc-nonPH. In addition, ID SSc-PH patients have a significantly worse survival compared with non-ID patients. Rheumatology (2014) 53 (2): 285-292. (Also see Pulmonary Hypertension and Anemia of Chronic Disease)

Go to Scleroderma Medical News: January 2014
Recent Donors
See ISN News for recent donors, including memorials for
Christine Kane, Joleen M. Cascaden.

SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA

Email [email protected] to request our Welcome email, or to report bad links or to update this page content.

TOLL FREE HOTLINE 800-564-7099
Free to U.S. and Canadian Callers. Ask for our Free Info Packet by mail or email!
Scleroderma, Pulmonary Arterial Hypertension, and related illnesses.
Privacy Policy.

The most important thing in the world to know about scleroderma is!
Donate Now
Copyright 1998-2017, International Scleroderma Network. AKA Scleroderma from A to Z and SCLERO.ORG. All Rights Reserved.